Should I buy or sell Eton Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ETON shares. View ETON analyst ratings or view top-rated stocks .

What is Eton Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Eton Pharmaceuticals' shares. Their ETON share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 220.5% from the stock's current price. View analysts price targets for ETON or view top-rated stocks among Wall Street analysts .

How have ETON shares performed in 2024?

Eton Pharmaceuticals' stock was trading at $4.38 at the beginning of the year. Since then, ETON shares have decreased by 28.8% and is now trading at $3.12. View the best growth stocks for 2024 here .

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 220,400 shares, a drop of 9.3% from the March 15th total of 242,900 shares. Based on an average daily volume of 70,600 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.0% of the company's shares are short sold. View Eton Pharmaceuticals' Short Interest .

When is Eton Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ETON earnings forecast .

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The firm had revenue of $7.31 million for the quarter, compared to analyst estimates of $7.70 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 6.21% and a negative net margin of 2.96%.

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Amarin (AMRN) , Myovant Sciences (MYOV) , Dynavax Technologies (DVAX) , Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , CymaBay Therapeutics (CBAY) , Fulcrum Therapeutics (FULC) and Moderna (MRNA) .

When did Eton Pharmaceuticals IPO?

Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:ETON

Eton Pharmaceuticals (ETON) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free ETON Stock Alerts

$3.09

+0.03 (+0.98%)

(As of 12:58 PM ET)

Compare

Today's Range: $3.04
▼
$3.15
50-Day Range: $3.06
▼
$4.59
52-Week Range: $2.42
▼
$5.81

Volume: 20,335 shs
Average Volume: 68,630 shs
Market Capitalization: $79.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Eton Pharmaceuticals alerts:

Eton Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 220.5% Upside
$10.00 Price Target
Short Interest: Healthy
0.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

Medical Sector

499th out of 918 stocks

Pharmaceutical Preparations Industry

228th out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Eton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Eton Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.98% of the float of Eton Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Eton Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eton Pharmaceuticals has recently decreased by 9.26%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Eton Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eton Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ETON.

2.7

News and Social Media Coverage

News Sentiment
Eton Pharmaceuticals has a news sentiment score of 1.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Eton Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for ETON on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.16% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.86% of the stock of Eton Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Eton Pharmaceuticals is -104.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eton Pharmaceuticals is -104.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eton Pharmaceuticals has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About Eton Pharmaceuticals Stock (NASDAQ:ETON)

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

ETON Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ETON Stock News Headlines

March 22, 2024 | markets.businessinsider.com

Eton Pharma Buys U.S. Rights To PKU GOLIKE From Relief Therapeutics

March 22, 2024 | finance.yahoo.com

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

March 22, 2024 | globenewswire.com

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

March 17, 2024 | theguardian.com

‘I don’t think I developed emotionally’: Earl Spencer on the pain of boarding-school abuse

March 17, 2024 | investing.com

Earnings call: Eton Pharmaceuticals reports robust Q4 growth

March 16, 2024 | finance.yahoo.com

ETON Apr 2024 5.000 call

March 16, 2024 | seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

March 16, 2024 | benzinga.com

Recap: Eton Pharmaceuticals Q4 Earnings

March 15, 2024 | finance.yahoo.com

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript

March 15, 2024 | finance.yahoo.com

Q4 2023 Eton Pharmaceuticals Inc Earnings Call

March 14, 2024 | finance.yahoo.com

Eton Pharmaceuticals Inc (ETON) Reports Robust Sales Growth and Pipeline Progress in Q4 and ...

March 14, 2024 | globenewswire.com

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024 | benzinga.com

Eton Pharmaceuticals Earnings Preview

March 13, 2024 | msn.com

Eton Pharmaceuticals Q4 2023 Earnings Preview

March 13, 2024 | markets.businessinsider.com

Eton Pharmaceuticals earnings preview: what Wall Street is expecting

March 13, 2024 | msn.com

Earl Spencer’s horrific first experience of sex was all too typical for an upper-class male

March 12, 2024 | thetimes.co.uk

Charles Spencer: ‘Boarding school killed a part of me’

March 11, 2024 | washingtonpost.com

Princess Di’s brother, Charles Spencer, recounts childhood horrors

March 11, 2024 | msn.com

Charles Spencer, Princess Diana’s brother, speaks out about ‘devastating’ abuse at British boarding school

March 11, 2024 | thetimes.co.uk

Boris Johnson’s secret flight to meet autocrat Maduro in Venezuela

March 11, 2024 | msn.com

Earl Spencer reveals abuse at boarding school

February 29, 2024 | globenewswire.com

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

February 22, 2024 | benzinga.com

Eton Pharmaceuticals Stock (NASDAQ:ETON) Dividends: History, Yield and Dates

February 21, 2024 | globenewswire.com

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

January 23, 2024 | finance.yahoo.com

Eton Pharmaceuticals (NASDAQ:ETON) investors are sitting on a loss of 50% if they invested three years ago

See More Headlines

Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ETON
CUSIP: N/A
CIK: 1710340
Web: www.etonpharma.com
Phone: (847) 787-7361
Fax: N/A
Employees: 30
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +220.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 12.00
P/E Growth: N/A
Net Income: $-940,000.00
Net Margins: -2.96%
Pretax Margin: -2.18%
Return on Equity: -6.21%
Return on Assets: -3.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.65
Quick Ratio: 1.60

Sales & Book Value

Annual Sales: $31.64 million
Price / Sales: 2.53
Cash Flow: $0.00 per share
Price / Cash Flow: 982.54
Book Value: $0.60 per share
Price / Book: 5.20

Miscellaneous

Outstanding Shares: 25,690,000
Free Float: 22,307,000
Market Cap: $80.15 million
Optionable: Optionable
Beta: 1.17

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Sean E. Brynjelsen (Age 52)
President, CEO & Director
Comp: $868.13k
Mr. James R. Gruber CPA (Age 52)
CFO, Treasurer & Secretary
Comp: $457.58k
Mr. David C. Krempa (Age 35)
Chief Business Officer
Ms. Ingrid Hoos
Senior Vice President of Regulatory Affairs
Mr. Kevin Guthrie
Executive VP of Commercial Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ETON Stock Analysis - Frequently Asked Questions

Should I buy or sell Eton Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ETON shares.
View ETON analyst ratings or view top-rated stocks.
What is Eton Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued twelve-month target prices for Eton Pharmaceuticals' shares. Their ETON share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 220.5% from the stock's current price.
View analysts price targets for ETON or view top-rated stocks among Wall Street analysts.
How have ETON shares performed in 2024?: Eton Pharmaceuticals' stock was trading at $4.38 at the beginning of the year. Since then, ETON shares have decreased by 28.8% and is now trading at $3.12.
View the best growth stocks for 2024 here.
Are investors shorting Eton Pharmaceuticals?: Eton Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 220,400 shares, a drop of 9.3% from the March 15th total of 242,900 shares. Based on an average daily volume of 70,600 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.0% of the company's shares are short sold.
View Eton Pharmaceuticals' Short Interest.
When is Eton Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ETON earnings forecast.

How were Eton Pharmaceuticals' earnings last quarter?: Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The firm had revenue of $7.31 million for the quarter, compared to analyst estimates of $7.70 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 6.21% and a negative net margin of 2.96%.
What other stocks do shareholders of Eton Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).
When did Eton Pharmaceuticals IPO?: Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.
How do I buy shares of Eton Pharmaceuticals?: Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ETON) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial